Divarasib clinical trials
Also written GDC-6036.
How each study uses divarasib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the divarasib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
13 studies that test it; most in 2024 (3)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 13 · Other 0
Often tested with
Tested in the same studies.
Alectinib (3) · Entrectinib (3) · Atezolizumab (3) · Vemurafenib (2) · Cobimetinib (2) · Pralsetinib (2) · Inavolisib (2) · Bevacizumab (2)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test divarasib, phase 3 first.
- Jun 2027A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)Phase 2/3 · Hoffmann-La Roche
- Nov 2026A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)Phase 2 · Genentech, Inc.
Studies
Open first, then newest update. How each study uses divarasib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 13
- A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 3Hoffmann-La RocheNCT07541170Written as Divarasib
- A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)RecruitingPhase 1Hoffmann-La RocheNCT04929223Written as Divarasib
- A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C MutationRecruitingPhase 1/2Hoffmann-La RocheNCT05789082Written as Divarasib
- A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerRecruitingPhase 3Hoffmann-La RocheNCT06793215Written as Divarasib
- A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)Active, not recruitingPhase 2Genentech, Inc.NCT04302025Written as Divarasib
- A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingPhase 3Hoffmann-La RocheNCT06497556Written as Divarasib
- Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyActive, not recruitingPhase 2Hoffmann-La RocheNCT04589845Written as Divarasib
- A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingPhase 2/3Hoffmann-La RocheNCT03178552Written as Divarasib
- A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C MutationActive, not recruitingPhase 1Genentech, Inc.NCT04449874Written as GDC-6036
- A Study to Evaluate the Pharmacokinetics of Divarasib in Healthy Participants and Participants With Impaired Hepatic FunctionCompletedPhase 1Genentech, Inc.NCT06734208Written as Divarasib
- A Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Divarasib in Healthy ParticipantsCompletedPhase 1Genentech, Inc.NCT06835465Written as Divarasib
- A Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Divarasib in Healthy ParticipantsCompletedPhase 1Genentech, Inc.NCT06690138Written as Divarasib
- A Clinical Trial to Investigate the Clinical Drug-Drug Interaction of Divarasib With Probe Substrates of P-Glycoprotein and Breast Cancer Resistance Protein in Healthy ParticipantsCompletedPhase 1Genentech, Inc.NCT06677957Written as Divarasib
Given beside what is tested · 1 — divarasib is usual care or a partner of the new treatment
Codes
What other systems call divarasib · ClinicalTrials.gg INT016425
- UNII (FDA) E6S21PVT91DIVARASIBConfirmed FDA, Wikidata
- Wikidata Q123118541divarasibConfirmed FDA, Wikidata
- NCI Thesaurus C173995DivarasibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | E6S21PVT91 | DIVARASIB | Confirmed FDA, Wikidata |
| Wikidata | Q123118541 | divarasib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C173995 | Divarasib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.